- What is Nextage Therapeutics' primary focus?
- Nextage Therapeutics specializes in targeted nano-liposomes based drug delivery across the blood-brain-barrier, with a lead drug candidate under development for glioblastoma treatment.
- When was Nextage Therapeutics founded?
- Nextage Therapeutics was founded in March 2006.
- What is the current employee count for Nextage Therapeutics?
- Nextage Therapeutics has 11-50 employees.
- What is Nextage Therapeutics' market capitalization?
- Nextage Therapeutics has a market capitalization of $7,257,424 USD.
- What additional services does Nextage Therapeutics provide through its subsidiary?
- Through its subsidiary Nextar Chempharma Solutions, Nextage Therapeutics provides development and commercial manufacturing services for pharmaceuticals and medical devices, including drug substance synthesis, formulation development, and sterile manufacturing.
- What is the current status of Nextage Therapeutics?
- Nextage Therapeutics is an active company and has been public on TASE since August 2020.
- Does Nextage Therapeutics hold any patents?
- Yes, Nextage Therapeutics holds 1 patent.
- Who is the CEO of Nextage Therapeutics?
- The CEO of Nextage Therapeutics is Ilan Avni.
